17 Facts About Genzyme


Genzyme was an American biotechnology company based in Cambridge, Massachusetts.

FactSnippet No. 1,401,555

In 2006 and 2007, Genzyme was named one of Fortune magazine's “100 Best Companies to Work for”.

FactSnippet No. 1,401,556

Genzyme donated $83 million worth of products worldwide; in 2006, it made $11 million in cash donations.

FactSnippet No. 1,401,557

In 2005, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the president of the United States to America's leading innovators.

FactSnippet No. 1,401,558

Genzyme's first office was an old clothing warehouse adjacent to Tufts Medical School.

FactSnippet No. 1,401,559

Genzyme was scheduled for a spleen removal but his mother pleaded with Roscoe Brady, MD, and expert in Gaucher's disease, to include Brian in the clinical trial of Ceredase along with the other seven patients who were all adults.

FactSnippet No. 1,401,560

In 1991, Genzyme took IG laboratories, acquired in 1989, public raising $14 million on IPO.

FactSnippet No. 1,401,561

Genzyme's sold off its interest in GENE-TRAK systems for $10 million and acquired Genecore International's diagnostic enzyme division.

FactSnippet No. 1,401,562

In 1992, Genzyme acquired Medix Biotech, Inc, a producer and supplier of monoclonal and polyclonal antibodies, immunoassay components, and immunodiagnostic services.

FactSnippet No. 1,401,563

In 1994, Genzyme received FDA approval to market Cerezyme, a genetically engineered replacement for Ceredase.

FactSnippet No. 1,401,564

Genzyme acquired Sygena Ltd, BioSurface Technology Inc and TSI Inc.

FactSnippet No. 1,401,565

In 2004, the company acquired Ilex Oncology Inc Genzyme acquired several of Impath's laboratories and cancer-testing technologies in May 2004, after Impath sought Chapter 11 bankruptcy protection.

FactSnippet No. 1,401,566

In 2010, the year before the company's acquisition by Sanofi-Aventis, Genzyme had more than $400 million on net income on revenue of $4 billion and was the fourth-largest American biopharmaceutical company.

FactSnippet No. 1,401,567

Genzyme focuses on six areas of medicine relating to lysosomal storage diseases, renal disease, orthopedics, transplant and immune diseases, oncology, genetics and diagnostics.

FactSnippet No. 1,401,568

Genzyme had a sub-license from Bioenvision to market clofarabine in North America.

FactSnippet No. 1,401,569

In 2010, Genzyme launched a kidney medication for the Irish market from its Waterford base which it had set up nine years previously.

FactSnippet No. 1,401,570

Genzyme was claimed to be in violation of the federal False Claims Act.

FactSnippet No. 1,401,571